Nektar Therapeutics (NKTR) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Nektar Therapeutics Revenue Highlights

Latest Revenue (Y)

$55.23M

Latest Revenue (Q)

$10.86M

Main Segment (Y)

Non Cash Royalty Revenue Related To Sale Of Future Royalties

Main Geography (Y)

Non-US

Nektar Therapeutics Revenue by Period

Nektar Therapeutics Revenue by Year

Date	Revenue	Change
2025-12-31	$55.23M	-43.89%
2024-12-31	$98.43M	9.22%
2023-12-31	$90.12M	-2.10%
2022-12-31	$92.06M	-9.67%
2021-12-31	$101.91M	-33.36%
2020-12-31	$152.91M	33.41%
2019-12-31	$114.62M	-90.40%
2018-12-31	$1.19B	287.81%
2017-12-31	$307.71M	86.00%
2016-12-31	$165.44M	-28.32%
2015-12-31	$230.78M	14.99%
2014-12-31	$200.71M	34.77%
2013-12-31	$148.92M	83.42%
2012-12-31	$81.19M	13.59%
2011-12-31	$71.48M	-55.06%
2010-12-31	$159.04M	121.10%
2009-12-31	$71.93M	-20.24%
2008-12-31	$90.19M	-66.97%
2007-12-31	$273.03M	25.40%
2006-12-31	$217.72M	72.41%
2005-12-31	$126.28M	10.51%
2004-12-31	$114.27M	7.54%
2003-12-31	$106.26M	12.03%
2002-12-31	$94.84M	22.43%
2001-12-31	$77.47M	50.05%
2000-12-31	$51.63M	24.83%
1999-12-31	$41.36M	89.76%
1998-12-31	$21.80M	34.13%
1997-12-31	$16.25M	135.49%
1996-12-31	$6.90M	102.94%
1995-12-31	$3.40M	100.00%
1994-12-31	$1.70M	-

Nektar Therapeutics generated $55.23M in revenue during NA 2025, up -43.89% compared to the previous quarter, and up 36.12% compared to the same period a year ago.

Nektar Therapeutics Revenue by Quarter

Date	Revenue	Change
2026-03-31	$10.86M	-50.19%
2025-12-31	$21.81M	84.96%
2025-09-30	$11.79M	5.50%
2025-06-30	$11.18M	6.84%
2025-03-31	$10.46M	-64.15%
2024-12-31	$29.18M	20.94%
2024-09-30	$24.12M	2.70%
2024-06-30	$23.49M	8.55%
2024-03-31	$21.64M	-9.40%
2023-12-31	$23.89M	-1.07%
2023-09-30	$24.14M	17.78%
2023-06-30	$20.50M	-5.07%
2023-03-31	$21.59M	-1.95%
2022-12-31	$22.02M	-6.78%
2022-09-30	$23.63M	9.45%
2022-06-30	$21.59M	-13.04%
2022-03-31	$24.82M	-0.75%
2021-12-31	$25.01M	0.35%
2021-09-30	$24.92M	-12.03%
2021-06-30	$28.33M	19.80%
2021-03-31	$23.65M	0.79%
2020-12-31	$23.46M	-21.88%
2020-09-30	$30.03M	-38.52%
2020-06-30	$48.85M	-3.41%
2020-03-31	$50.57M	49.35%
2019-12-31	$33.86M	15.89%
2019-09-30	$29.22M	25.32%
2019-06-30	$23.32M	-17.39%
2019-03-31	$28.22M	-29.14%
2018-12-31	$39.83M	43.46%
2018-09-30	$27.76M	-97.45%
2018-06-30	$1.09B	2761.06%
2018-03-31	$38.02M	-60.18%
2017-12-31	$95.47M	-37.57%
2017-09-30	$152.93M	342.13%
2017-06-30	$34.59M	39.88%
2017-03-31	$24.73M	-33.97%
2016-12-31	$37.45M	3.07%
2016-09-30	$36.34M	10.89%
2016-06-30	$32.77M	-44.35%
2016-03-31	$58.88M	49.56%
2015-12-31	$39.37M	-34.33%
2015-09-30	$59.95M	164.56%
2015-06-30	$22.66M	-79.17%
2015-03-31	$108.80M	456.47%
2014-12-31	$19.55M	-85.28%
2014-09-30	$132.87M	366.00%
2014-06-30	$28.51M	44.22%
2014-03-31	$19.77M	-36.52%
2013-12-31	$31.15M	-48.86%
2013-09-30	$60.91M	79.87%
2013-06-30	$33.86M	47.20%
2013-03-31	$23.00M	8.79%
2012-12-31	$21.15M	14.85%
2012-09-30	$18.41M	-22.26%
2012-06-30	$23.68M	31.95%
2012-03-31	$17.95M	13.73%
2011-12-31	$15.78M	-41.69%
2011-09-30	$27.07M	56.18%
2011-06-30	$17.33M	53.39%
2011-03-31	$11.30M	-75.07%
2010-12-31	$45.31M	19.48%
2010-09-30	$37.92M	-10.90%
2010-06-30	$42.56M	28.06%
2010-03-31	$33.24M	-14.80%
2009-12-31	$39.01M	281.58%
2009-09-30	$10.22M	-21.29%
2009-06-30	$12.99M	33.75%
2009-03-31	$9.71M	-65.75%
2008-12-31	$28.35M	32.25%
2008-09-30	$21.44M	5.09%
2008-06-30	$20.40M	2.05%
2008-03-31	$19.99M	-69.60%
2007-12-31	$65.77M	-

Nektar Therapeutics generated $10.86M in revenue during Q1 2026, up -50.19% compared to the previous quarter, and up 37.23% compared to the same period a year ago.

Nektar Therapeutics Revenue Breakdown

Nektar Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Non Cash Royalty Revenue Related To Sale Of Future Royalties	$54.93M	$64.27M	$68.92M	$69.79M	$77.75M
License Collaboration And Other Revenue	$300.00K	$597.00K	$520.00K	$1.91M	$436.00K
Product	-	$33.56M	$20.68M	$20.35M	$23.73M
Royalty	-	-	-	-	-

Nektar Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 25: Non Cash Royalty Revenue Related To Sale Of Future Royalties (99.46%), and License Collaboration And Other Revenue (0.54%).

Quarterly Revenue by Product

Product/Service	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
Non Cash Royalty Revenue Related To Sale Of Future Royalties	$10.86M	$21.81M	$11.49M	$11.18M	$10.46M	$33.03M	$15.73M	$15.51M	$18.06M	$18.17M	$15.83M	$16.86M	$17.63M	$18.34M	$16.26M	$17.56M	$19.08M	$19.41M	$20.46M	$18.80M
License Collaboration And Other Revenue	-	-	$300.00K	$122.00K	$378.00K	$97.00K	$341.00K	$155.00K	$9.00K	$15.00K	$17.00K	$314.00K	$9.00K	$1.57M	$40.00K	$314.00K	$28.00K	$54.00K	-	-
Product	-	-	-	-	-	$19.51M	$8.02M	$6.03M	$5.48M	$5.82M	$4.66M	$4.72M	$4.38M	$4.97M	$5.31M	$5.69M	$5.89M	$5.19M	$7.85M	$4.79M
Royalty	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Nektar Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 26: Non Cash Royalty Revenue Related To Sale Of Future Royalties (100.00%).

Nektar Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Non-US	$55.23M	$97.05M	$78.64M	$82.21M	$91.79M
UNITED STATES	-	$1.38M	$11.48M	$9.84M	$10.11M

Nektar Therapeutics's latest annual revenue breakdown by geography, as of Dec 25: Non-US (100.00%).

Nektar Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
SNDX	Syndax Pharmaceuticals	$172.35M	$64.86M
NKTR	Nektar Therapeutics	$55.23M	$10.86M
IMTX	Immatics	$54.00M	$30.45M
RLAY	Relay Therapeutics	$15.36M	$3.00M
INBX	Inhibrx Biosciences	$1.30M	-
ATAI	Atai Beckley N.V	-	$749.00K
ELVN	Enliven Therapeutics	-	-
SANA	Sana Bio	-	-
XNCR	Xencor	-	$43.61M
AMLX	Amylyx Pharmaceuticals	-	-
ORIC	ORIC Pharmaceuticals	-	-

NKTR Revenue FAQ

What is Nektar Therapeutics’s yearly revenue?

Nektar Therapeutics's yearly revenue for 2025 was $55.23M, representing a decrease of -43.89% compared to 2024. The company's yearly revenue for 2024 was $98.43M, representing an increase of 9.22% compared to 2023. NKTR's yearly revenue for 2023 was $90.12M, representing a decrease of -2.10% compared to 2022.

What is Nektar Therapeutics’s quarterly revenue?

Nektar Therapeutics's quarterly revenue for Q1 2026 was $10.86M, a -50.19% decrease from the previous quarter (Q4 2025), and a 3.83% increase year-over-year (Q1 2025). The company's quarterly revenue for Q4 2025 was $21.81M, a 84.96% increase from the previous quarter (Q3 2025), and a -25.25% decrease year-over-year (Q4 2024). NKTR's quarterly revenue for Q3 2025 was $11.79M, a 5.50% increase from the previous quarter (Q2 2025), and a -51.13% decrease year-over-year (Q3 2024).

What is Nektar Therapeutics’s revenue growth rate?

Nektar Therapeutics's revenue growth rate for the last 3 years (2023-2025) was -38.71%, and for the last 5 years (2021-2025) was -45.80%.

What are Nektar Therapeutics’s revenue streams?

Nektar Therapeutics's revenue streams in c 25 are Non Cash Royalty Revenue Related To Sale Of Future Royalties, and License Collaboration And Other Revenue. Non Cash Royalty Revenue Related To Sale Of Future Royalties generated $54.93M in revenue, accounting 99.46% of the company's total revenue, down -14.53% year-over-year. License Collaboration And Other Revenue generated $300K in revenue, accounting 0.54% of the company's total revenue, down -49.75% year-over-year.

What is Nektar Therapeutics’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Nektar Therapeutics was Non Cash Royalty Revenue Related To Sale Of Future Royalties. This segment made a revenue of $54.93M, representing 99.46% of the company's total revenue.